GlassScriptPhysician profile
Nathan Lingle
NPI 1649938945
$809.56
in general payments reported to CMS, 2019-2025
10 companies · $541 in 2025
The $541 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.15 · 2023: $12.69 · 2024: $225 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $216.96 | 2024-2025 | Trelegy Ellipta |
| Electromed, INC. | $148.74 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.90 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $65.63 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $60.50 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $53.98 | 2025 | Glassia |
| 3b Medical, INC. | $45.50 | 2024-2025 | Luna |
| Mallinckrodt Hospital Products INC. | $36.24 | 2024 | Acthar |
| Abbvie INC. | $33.43 | 2025 | |
| Genzyme Corporation | $21.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Lingle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.